pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,502 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1890Endpoints1465Fierce Biotech779BioSpace767BioPharma Dive555raps254onclive165fda recalls
therapy area
allOncology13094Rare Disease3387Immunology3069Cardiology2866Hematology2335Pulmonology2299Vaccines
  • RevMed's Rasonque shows strong first-line response and survival benefit in early pancreatic cancer data
    RevMed reported early-stage results from its open‑label Phase 1/2 RMC‑GI‑102 trial, presented at the EORTC‑N conference, evaluating Rasonque combined with chemotherapy in patients with first‑line m…
    BioSpace · 6h agoPositive readoutPositive↗ source
  • Sanofi weighs $40 billion Insmed acquisition, seen as strategic fit in respiratory market
    Analysts are reporting that Sanofi is considering buying Insmed, a biotech focused on respiratory therapies. The potential transaction could be valued at up to $40 billion, making it one of the lar…
    BioSpace · 6h agoDealPositive
← prev
page 1 of 61
next →
123
fda medwatch118
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
↗ source
  • Compass Pathways and Usona Institute vie for first FDA approval of a psilocybin depression therapy
    Compass Pathways and Usona Institute are both positioning themselves to become the first company with an FDA-approved psilocybin therapy for treatment-resistant depression. Compass has long been s…
    BioPharma Dive · 1h agoRegulatoryNeutral↗ source
  • Erasca reports 44% response in KRAS-mutated pancreatic cancer, eyes Phase 3 trial
    Erasca announced that 44% of patients with KRAS-mutated pancreatic cancer showed a response to its experimental drug ERAS-0015 in a small Phase 1 study. The company said the treatment was well tole…
    BioPharma Dive · 3h agoPositive readoutNeutral↗ source
  • Merck-Kelun ADC sac-TMT shows overall survival benefit in Phase 3 stomach cancer trial
    Merck, licensing the TROP2-targeting antibody drug conjugate sac-TMT from Kelun-Biotech, reported that the therapy improved overall survival in patients with advanced gastroesophageal adenocarcinom…
    BioSpace · 6h agoPositive readoutPositive↗ source
  • China-origin biotech deals and IPOs surge as investors reap early returns, while Summit Therapeutics shares slump
    Biotech firms built around medicines originating in China have accelerated both acquisitions and initial public offerings this year, according to recent data visualizations. The large pool of Chin…
    BioPharma Dive · 9h agoDealNeutral↗ source
  • FDA delays decision on Savara's rare lung disease therapy, pushing back deadline
    The FDA announced it will not meet the Nov. 22 PDUFA date for Savara's biologics license application for its inhaled therapy molgramostim (Molbreevi) targeting autoimmune pulmonary alveolar protein…
    BioSpace · 5h agoRegulatoryNegative↗ source
  • Celldex halts eczema development of barzolvolimab after Phase 2 miss, eyes chronic hives filing
    Celldex Therapeutics announced it will stop developing its lead antibody barzolvolimab for eczema after the Phase 2 trial did not meet its internal efficacy threshold. The company said it will sti…
    BioPharma Dive · 8h agoNegative readoutNegative↗ source
  • Heraeus Medevio issues recall of vascular guidewires over coating safety risk
    The FDA's Center for Devices and Radiological Health has posted an Early Alert warning about a potentially high‑risk issue with certain vascular guidewires. The alert notes that the coating on the…
    fda medwatch · 16h agoRegulatoryNegative↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 5h agoLayoffsNegative↗ source
  • Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
    Licensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.
    BioSpace · 6h ago↗ source
  • Breckenridge Pharmaceutical, Inc. Issues Voluntary Nationwide Consumer-Level Recall of One Lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, Due to Potential Metal Contamination
    November 16, 2026— Breckenridge Pharmaceutical, Inc. (Breckenridge) is voluntarily recalling to the consumer level one lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, manufa…
    fda medwatch · 16h ago↗ source
  • FDA approves Regeneron's first siRNA therapy for generalized myasthenia gravis
    The FDA has granted approval for Regeneron's siRNA drug Livsayis (cemdisiran) for adult patients with generalized myasthenia gravis who are positive for anti‑acetylcholine receptor antibodies. Thi…
    BioSpace · 1d agoApprovalPositive↗ source
  • US panel warns China’s biotech plan could dominate sector and threaten drug supply chain
    A congressional commission has warned that China’s new five-year biotech plan could allow it to dominate the global drug market. The commission says the strategy could leave U.S. patients vulnerab…
    BioPharma Dive · 1d agoRegulatoryNegative↗ source
  • FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravis
    The Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
    BioPharma Dive · 1d agoApprovalPositive↗ source
  • AbbVie signs up to $2.5 B licensing deal with DISCO to develop solid tumor bispecific therapies
    AbbVie announced a licensing agreement with European biotech DISCO Pharmaceuticals that could be worth as much as $2.5 billion. The deal includes a $40 million upfront payment and future milestones…
    BioSpace · 1d agoDealPositive↗ source
  • Sanofi receives FDA clearance for Infilbray, first pill to treat neurological symptoms of Type 3 Gaucher disease
    Sanofi received FDA clearance for Infilbray, a once-daily pill for Type 3 Gaucher disease in adults and children weighing at least 15 kilograms. The drug, inherited from Sanofi’s 2011 acquisition…
    BioPharma Dive · 1d agoApprovalPositive↗ source
  • Novartis forecasts modest 5% growth, bets on pipeline as Kisqali loses patent
    Novartis told investors it expects slower top‑line growth, narrowing its sales guidance to about 5% annual increase through 2031 as the breast‑cancer drug Kisqali faces patent expiry and price pres…
    BioSpace · 1d agoNeutral↗ source
  • Nine California biotech firms slash at least half of their workforces amid statewide cuts
    Workforce reductions have affected more than 1,000 biopharma employees in California so far this year, with the hardest hits falling on biotech firms. Nine companies have announced plans to cut at…
    BioSpace · 1d agoLayoffsNegative↗ source
  • Outset Medical issues safety alert for Tablo dialysis system power cords overheat risk
    The FDA’s Center for Devices and Radiological Health has posted an Early Alert after learning that certain power cords used with Outset Medical’s Tablo hemodialysis consoles and the TabloCart with…
    fda medwatch · 1d agoRegulatoryNeutral↗ source
  • Actinogen’s Alzheimer’s drug Xanamem fails pivotal trial, shares plunge over 80%
    Actinogen Medical, an Australian biotech, reported that its only candidate, Xanamem (emestedastat), did not meet the primary endpoint in a Phase 2b/3 study in patients with mild to moderate Alzheim…
    BioSpace · 1d agoNegative readoutNegative↗ source
  • FDA puts drug repurposing front-and-center, says BioSpace podcast
    In a recent episode of BioSpace’s podcast “Denatured,” host Jennifer C. Smith-Parker spoke with Daniel Tillett, chief executive of Racura Oncology, and Sten Sörensen, chief executive of Cereno Scie…
    BioSpace · 1d agoRegulatoryNeutral↗ source
  • Early Alert: B. Braun Medical Inc. Updates Use Instructions for Caresite Micro Luer Access Device
    BBMI corrects Caresite devices due to issue with internal piston remaining depressed following disconnection, preventing the valve from fully closing.
    fda medwatch · 1d agoRegulatoryNeutral↗ source
  • Three series-C funded biotechs expand hiring, including Triveni Bio’s $65 M raise
    Three biotechnology companies that announced series C financing this year are actively hiring, signaling plans to scale operations. One of the firms secured a $140 million round and maintains offic…
    BioSpace · 1d agoDealNeutral↗ source
  • Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
    Sanofi’s Infilbray is designed to cross the blood-brain barrier, allowing the drug to prevent the toxic buildup of disease-causing lipids in the brain for patients with type 3 Gaucher disease.
    BioSpace · 1d ago↗ source